AXGN
Axogen, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Neutral
-1/100
Last price
37.91
▲ 0.69 (1.85%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
37.46
Prev close
37.22
Day high
37.61
Day low
35.82
Volume
2.35M
Market cap
$2.13B
P/E (TTM)
—
52W range
15.27 – 52.91
Day trading desk
Gap from prior close
+0.64%
Prior close 37.22
VWAP
36.37
+4.24% from price
Relative volume
3.66×
Unusually busy
Session range
5.95%
35.82 – 37.95
Position in range
98%
Near session high
ATR (14D)
1.92
5.06% of price
Prior day high
38.27
PDH
Prior day low
36.79
PDL
Bid / ask spread
—
Quote not published
Session volume
4.46M
Avg 1.22M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-14.44%
-16.4%
1M
-24.79%
-25.9%
3M
-15.06%
-19.6%
6M
+17.17%
-1.0%
YTD
+10.94%
-3.3%
1Y
+103.08%
+86.7%
3Y
+626.20%
+543.9%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on AXGN open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+82.65K
Net buying
Buy transactions
13
219.12K shares
Sell transactions
10
136.47K shares
Net transactions
+23
Buys less sells
Sell : buy shares
0.6 : 1
Mixed
Insider-held shares
1.06M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 2, 26 | TYNDALL JOSEPH A Director |
SELL | 3.50K | $173.94K | Direct |
| Aug 11, 26 | MCBRIDE-WENDELL AMY A. Director |
SELL | 13.35K | $646.59K | Direct |
| Aug 11, 26 | MCBRIDE-WENDELL AMY A. Director |
CONVERSION | 13.35K | $198.29K | Direct |
| Aug 10, 26 | BEGAN MARC A. General Counsel |
SELL | 67.50K | $3.20M | Direct |
| Aug 10, 26 | BEGAN MARC A. General Counsel |
CONVERSION | 67.50K | $550.80K | Direct |
| Aug 7, 26 | WEILER KATHY JOHNSON Director |
SELL | 14.15K | $640.97K | Direct |
| Jun 18, 26 | THOMAS PAUL G Director |
— | 18.87K | — | Direct |
| Jun 18, 26 | MCBRIDE-WENDELL AMY A. Director |
— | 14.15K | — | Direct |
| Jun 18, 26 | BURKE WILLIAM P. Director |
— | 14.15K | — | Direct |
| Jun 18, 26 | LEVINE ALAN M. Director |
— | 14.15K | — | Direct |
| Jun 18, 26 | TYNDALL JOSEPH A Director |
— | 14.15K | — | Direct |
| Jun 18, 26 | WEILER KATHY JOHNSON Director |
— | 14.15K | — | Direct |
| Jun 18, 26 | JOHNSON JOHN H. Director |
— | 14.15K | — | Direct |
| May 8, 26 | MCBRIDE-WENDELL AMY A. Director |
SELL | 1.65K | $70.16K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BEGAN MARC A. |
General Counsel | 50.13K | Conversion of Exercise of derivative security |
DALE MICHAEL D |
Chief Executive Officer | 63.54K | Sale |
DEVINNEY ERICK WAYNE |
Officer | 262.78K | Sale |
HARTLEY LINDSEY MARIE |
Chief Financial Officer | 65.15K | Sale |
KEMP JENS SCHROEDER |
Officer | 72.45K | Sale |
LEVINE ALAN M. |
Director | 50.89K | Conversion of Exercise of derivative security |
MCBRIDE-WENDELL AMY A. |
Director | 107.98K | Conversion of Exercise of derivative security |
NEELS GUIDO J |
Director | 86.74K | Sale |
QUACKENBUSH DORIS |
Officer | 92.42K | Sale |
THOMAS PAUL G |
Director | 32.40K | Conversion of Exercise of derivative security |
Fundamentals
Market cap$2.13B
Enterprise value$1.86B
Revenue (TTM)$251.17M
Gross profit$187.26M
EBITDA$-5.97M
Net income$-33.55M
EPS (TTM)$-0.65
Free cash flow$18.23M
Total cash$111.41M
Total debt$20.07M
Book value / share$4.78
Shares outstanding58.67M
Float49.06M
Short % of float7.89%
Dividend yield0.00%
Beta (5Y)1.17
Valuation & profitability ratios
Trailing P/E—
Forward P/E50.85
PEG ratio99.04
Price / sales—
Price / book7.60
EV / revenue7.41
EV / EBITDA-311.79
Gross margin74.56%
Operating margin-3.09%
Profit margin-13.36%
Return on equity-18.21%
Return on assets-3.15%
Debt / equity7.83
Current ratio6.60
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $225.21M | $187.34M | $159.01M | $138.58M | +20.2% |
| Operating revenue | $225.21M | $187.34M | $159.01M | $138.58M | +20.2% |
| Cost of revenue | $57.85M | $45.36M | $37.14M | $29.77M | +27.5% |
| Gross profit | $167.35M | $141.98M | $121.87M | $108.81M | +17.9% |
| Research & development | $32.88M | $27.77M | $27.34M | $25.63M | +18.4% |
| Selling, general & admin | $142.32M | $117.50M | $115.99M | $112.89M | +21.1% |
| Total operating expense | $175.20M | $145.26M | $143.33M | $138.52M | +20.6% |
| Operating income | -$7.85M | -$3.29M | -$21.46M | -$29.71M | -138.8% |
| Net interest income | -$7.70M | -$8.21M | -$2.83M | -$624.00K | +6.1% |
| Pre-tax income | -$15.70M | -$9.96M | -$21.72M | -$28.95M | -57.6% |
| Net income | -$15.70M | -$9.96M | -$21.72M | -$28.95M | -57.6% |
| Net income to common | -$15.70M | -$9.96M | -$21.72M | -$28.95M | -57.6% |
| Basic EPS | -0.34 | -0.23 | -0.51 | -0.69 | -47.8% |
| Diluted EPS | -0.34 | -0.23 | -0.51 | -0.69 | -47.8% |
| EBIT | -$8.00M | -$1.76M | -$18.88M | -$28.32M | -355.1% |
| EBITDA | $507.00K | $6.08M | -$13.33M | -$23.47M | -91.7% |
| Basic shares | 46.05M | 44.26M | 42.88M | 42.08M | +4.1% |
| Diluted shares | 46.05M | 44.26M | 42.88M | 42.08M | +4.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $35.55M | $27.55M | $31.02M | $15.28M | +29.0% |
| Cash & short-term investments | $41.53M | $33.48M | $31.02M | $48.79M | +24.0% |
| Accounts receivable | $26.17M | $24.11M | $25.15M | $22.19M | +8.6% |
| Inventory | $42.37M | $33.18M | $23.02M | $18.91M | +27.7% |
| Total current assets | $120.42M | $99.22M | $88.00M | $98.08M | +21.4% |
| Property, plant & equipment | $94.52M | $98.93M | $104.29M | $93.66M | -4.5% |
| Goodwill & intangibles | $6.75M | $5.58M | $4.53M | $3.65M | +21.0% |
| Total assets | $221.69M | $203.73M | $196.83M | $195.39M | +8.8% |
| Total current liabilities | $23.56M | $30.61M | $30.43M | $23.75M | -23.0% |
| Long-term debt | $48.39M | $47.50M | $46.60M | $45.71M | +1.9% |
| Total debt | $67.63M | $68.69M | $69.29M | $67.43M | -1.5% |
| Total liabilities | $92.84M | $99.82M | $101.16M | $94.39M | -7.0% |
| Retained earnings | -$306.96M | -$291.26M | -$281.30M | -$259.58M | -5.4% |
| Shareholder equity | $128.85M | $103.91M | $95.67M | $101.00M | +24.0% |
| Working capital | $96.87M | $68.61M | $57.57M | $74.32M | +41.2% |
| Net tangible assets | $122.10M | $98.33M | $91.13M | $97.35M | +24.2% |
| Shares issued | 47.20M | 44.15M | 43.12M | 42.45M | +6.9% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$15.70M | -$9.96M | -$21.72M | -$28.95M | -57.6% |
| Depreciation & amortisation | $8.51M | $7.84M | $5.55M | $4.85M | +8.6% |
| Stock-based compensation | $30.11M | $15.91M | $14.42M | $15.59M | +89.3% |
| Change in working capital | -$24.61M | -$10.04M | -$2.45M | -$7.79M | -145.1% |
| Operating cash flow | $812.00K | $4.54M | -$5.72M | -$16.07M | -82.1% |
| Capital expenditure | -$5.59M | -$4.52M | -$14.92M | -$21.25M | -23.7% |
| Investing cash flow | -$5.32M | -$10.30M | $19.25M | -$3.20M | +48.4% |
| Financing cash flow | $10.50M | $2.29M | $1.95M | $1.79M | +358.5% |
| Free cash flow | -$4.78M | $11.00K | -$20.63M | -$37.32M | -43,572.7% |
| End cash position | $39.55M | $33.55M | $37.03M | $21.54M | +17.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $69.73M | $61.46M | $59.90M | $60.08M | $56.66M | +13.5% |
| Operating revenue | $69.73M | $61.46M | $59.90M | $60.08M | $56.66M | +13.5% |
| Cost of revenue | $19.06M | $15.27M | $15.49M | $14.09M | $14.64M | +24.8% |
| Gross profit | $50.67M | $46.19M | $44.41M | $45.99M | $42.02M | +9.7% |
| Research & development | $8.59M | $7.52M | $12.38M | $7.57M | $6.85M | +14.3% |
| Selling, general & admin | $44.24M | $41.50M | $41.80M | $36.52M | $33.49M | +6.6% |
| Total operating expense | $52.83M | $49.02M | $54.18M | $44.08M | $40.35M | +7.8% |
| Operating income | -$2.16M | -$2.83M | -$9.77M | $1.91M | $1.67M | +23.9% |
| Net interest income | -$1.00K | -$694.00K | -$1.72M | -$1.76M | -$1.98M | +99.9% |
| Pre-tax income | -$1.52M | -$19.58M | -$13.16M | $708.00K | $579.00K | +92.3% |
| Net income | -$1.52M | -$19.58M | -$13.16M | $708.00K | $579.00K | +92.3% |
| Net income to common | -$1.52M | -$19.58M | -$13.16M | $708.00K | $579.00K | +92.3% |
| Basic EPS | -0.03 | -0.38 | -0.28 | 0.02 | 0.01 | +92.1% |
| Diluted EPS | -0.03 | -0.38 | -0.28 | 0.01 | 0.01 | +92.1% |
| EBIT | -$1.51M | -$18.89M | -$11.44M | $2.46M | $2.56M | +92.0% |
| EBITDA | $637.00K | -$16.77M | -$8.47M | $4.30M | $4.38M | +103.8% |
| Basic shares | 53.34M | 51.59M | 46.93M | 46.49M | 46.06M | +3.4% |
| Diluted shares | 53.34M | 51.59M | 46.93M | 49.09M | 47.98M | +3.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $94.57M | $82.65M | $35.55M | $23.90M | $20.04M | — | +14.4% |
| Cash & short-term investments | $111.41M | $101.60M | $41.53M | $35.79M | $29.92M | — | +9.7% |
| Accounts receivable | $34.13M | $28.31M | $26.17M | $30.77M | $28.03M | — | +20.5% |
| Inventory | $47.31M | $46.07M | $42.37M | $40.58M | $36.77M | — | +2.7% |
| Total current assets | $200.38M | $184.71M | $120.42M | $114.46M | $103.42M | — | +8.5% |
| Property, plant & equipment | $96.19M | $97.32M | $94.52M | $95.51M | $95.92M | — | -1.2% |
| Goodwill & intangibles | $7.57M | $7.27M | $6.75M | $6.43M | $6.12M | — | +4.1% |
| Total assets | $304.86M | $289.49M | $221.69M | $216.40M | $205.45M | — | +5.3% |
| Total current liabilities | $30.37M | $26.01M | $23.56M | $28.01M | $24.98M | — | +16.8% |
| Long-term debt | — | — | $48.39M | $48.16M | $47.94M | $47.72M | — |
| Total debt | $20.07M | $20.64M | $67.63M | $67.91M | $68.19M | — | -2.8% |
| Total liabilities | $48.61M | $44.68M | $92.84M | $95.59M | $93.18M | — | +8.8% |
| Retained earnings | -$328.06M | -$326.55M | -$306.96M | -$293.81M | -$294.51M | — | -0.5% |
| Shareholder equity | $256.26M | $244.81M | $128.85M | $120.81M | $112.28M | — | +4.7% |
| Working capital | $170.00M | $158.69M | $96.87M | $86.45M | $78.44M | — | +7.1% |
| Net tangible assets | $248.69M | $237.54M | $122.10M | $114.37M | $106.16M | — | +4.7% |
| Shares issued | 53.18M | 53.15M | 47.20M | 46.12M | 45.77M | — | +0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$1.52M | -$19.58M | -$13.16M | $708.00K | $579.00K | +92.3% |
| Depreciation & amortisation | $2.15M | $2.13M | $2.97M | $1.84M | $1.82M | +1.3% |
| Stock-based compensation | $8.77M | $6.84M | $16.61M | $5.42M | $5.17M | +28.1% |
| Change in working capital | -$2.11M | -$4.65M | -$5.63M | -$4.62M | $299.00K | +54.6% |
| Operating cash flow | $7.22M | $1.56M | $3.04M | $3.22M | $7.73M | +361.4% |
| Capital expenditure | -$1.75M | -$2.96M | -$1.96M | -$1.86M | -$1.11M | +41.0% |
| Investing cash flow | $500.00K | -$15.96M | $4.04M | -$3.75M | -$6.95M | +103.1% |
| Financing cash flow | $4.20M | $59.51M | $4.57M | $2.39M | $1.16M | -92.9% |
| Free cash flow | $5.47M | -$1.40M | $1.08M | $1.36M | $6.62M | +491.1% |
| End cash position | $96.57M | $84.65M | $39.55M | $27.90M | $26.04M | +14.1% |
Options analytics
Put / call volume
0.02
Call-heavy session
Put / call open interest
0.08
Positioning, not flow
Max pain
45.00
+23.9% from spot
ATM implied vol
64.0%
Nearest strike to spot
Skew (10% OTM)
-32.9%
Calls bid over puts
Call volume
1.03K
Contracts, this expiry
Put volume
16
Contracts, this expiry
Heaviest call OI
55.00
1.32K contracts
Heaviest put OI
50.00
244 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.12 | 0.12 | +1.2% |
| Mar 2026 | 0.07 | 0.07 | -2.0% |
| Dec 2025 | 0.10 | 0.07 | -27.9% |
| Sep 2025 | 0.07 | 0.12 | +76.5% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.13 | 8 | $73.13M | +21.7% |
| Next quarter | 0.13 | 4 | $81.17M | +35.5% |
| Current year | 0.47 | 4 | $285.50M | +26.8% |
| Next year | 0.71 | 5 | $367.33M | +28.7% |
Analyst targets & ownership
Mean target$53.70
High target$58.00
Low target$48.00
Implied upside41.65%
Analyst count10
ConsensusSTRONG BUY
Strong buy / Buy2 / 8
Hold0
Sell / Strong sell0 / 0
Held by insiders1.98%
Held by institutions97.95%
Institutions holding350
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
40.86
-7.22% from price
SMA 20
42.70
-14.97% from price
SMA 50
45.62
-20.41% from price
SMA 100
43.81
-13.47% from price
SMA 200
39.01
-6.91% from price
EMA 12
40.72
-6.90% from price
EMA 26
42.99
-11.81% from price
EMA 50
43.93
-13.69% from price
RSI (14)
25.5
Oversold
MACD (12,26,9)
-2.27
Hist -0.80
ATR (14)
1.92
5.29% of price
Realised vol 30D
51.1%
Annualised
Bollinger upper
48.49
20, 2σ
Bollinger lower
36.91
20, 2σ
50 / 200 cross
Golden
45.62 vs 39.01
Trend bias
Below 200
-6.91%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.78
Less volatile than market
Correlation to SPY
0.18
Largely independent
Realised vol 30D
51.1%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-29.8%
Peak to trough
Max drawdown 5Y
-76.9%
Peak to trough
ATR 14
1.92
5.29% of price
Beta (reported)
1.17
5Y monthly, from filing
Short interest
Shares short
4.06M
Prior 3.37M
Change vs prior
+20.5%
Shorts adding
% of float
7.89%
Normal
% of shares out
6.91%
Against total outstanding
Days to cover
3.5
Liquid
Float
49.06M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 1, 26 | Truist Securities | MAINTAINED | Buy | Buy |
| Sep 25, 26 | Raymond James | MAINTAINED | Outperform | Outperform |
| Aug 26, 26 | Truist Securities | INITIATED | — | Buy |
| Jul 30, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Jul 30, 26 | Citizens | MAINTAINED | Market Outperform | Market Outperform |
| Jul 30, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Apr 29, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Apr 29, 26 | Citizens | MAINTAINED | Market Outperform | Market Outperform |
| Apr 29, 26 | Wells Fargo | MAINTAINED | Overweight | Overweight |
| Apr 29, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Apr 23, 26 | Lake Street | MAINTAINED | Buy | Buy |
| Mar 30, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend dateJan 27, 2010
Next pay dateFeb 12, 2010
Last split105:100
Split dateJul 11, 1994
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-10-01
Corporate Changes & Voting Matters
8-K/A · 2026-09-10
Periodic Financial Reports
10-Q · 2026-07-29
Corporate Changes & Voting Matters
8-K · 2026-06-23
Proxy Statements
DEF 14A · 2026-04-29
Corporate Changes & Voting Matters
8-K · 2026-04-28
Periodic Financial Reports
10-K · 2026-02-24
Corporate Changes & Voting Matters
8-K · 2026-01-23
Headlines
Down 22.6% in 4 Weeks, Here's Why You Should You Buy the Dip in AxoGen (AXGN)
Zacks · 2d ago
Nasdaq Hits Fresh Ground on Chip and Software Strength as Dow, Small Caps Lag for the Week
CNW Group · 4d ago
Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair
GlobeNewswire · 5d ago
Truist Cuts Price Target on Axogen to $53 From $60, Keeps Buy Rating
MT Newswires · 6d ago
3 Emerging Biotech Stocks With Significant Upside Potential
MarketBeat · 6d ago
Axogen Raises $200 Million to Fund BioCircuit Buyout Focused on Sutureless Nerve Repair
Benzinga · 26d ago
2 Medical-Device Stocks Lighting Up the Options Pits
Schaeffer's Investment Research · 27d ago
Sector Update: Healthcare Stocks Mixed Pre-Bell Thursday
MT Newswires · 27d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.